Annexon, Inc. (ANNX) on Monday announced positive topline results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barr Syndrome, a rapid-onset and acute neuromuscular disease.
The company found that patients treated with ANX005 showed faster and greater improvement in muscle strength and disability compared to patients in the matched International GBS Outcomes Study cohort treated with IVIg or PE.
Also, ANX005-treated patients were observed to spend less time on ventilation and less time in the intensive care unit, and only a few of these patients required mechanical ventilation.
Following the promising results, the company plans to submit a U.S. Biologics License application in the first half of 2025.
Currently, Annexon's stock is climbing 11.15 percent, to $4.94 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.